## Maurizio Callari

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/114385/publications.pdf

Version: 2024-02-01

201674 189892 2,885 57 27 50 citations h-index g-index papers 61 61 61 6505 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell, 2016, 167, 260-274.e22.	28.9	376
2	Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature, 2019, 567, 399-404.	27.8	239
3	A transcriptional sketch of a primary human breast cancer by 454 deep sequencing. BMC Genomics, 2009, 10, 163.	2.8	205
4	Challenges in Using Circulating miRNAs as Cancer Biomarkers. BioMed Research International, 2015, 2015, 1-10.	1.9	202
5	miR-21: an oncomir on strike in prostate cancer. Molecular Cancer, 2010, 9, 12.	19.2	189
6	Clonal Decomposition and DNA Replication States Defined by Scaled Single-Cell Genome Sequencing. Cell, 2019, 179, 1207-1221.e22.	28.9	162
7	Bioinformatics tools for secretome analysis. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 2442-2453.	2.3	93
8	Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Research and Treatment, 2011, 127, 601-610.	2.5	88
9	Complexity in the tumour microenvironment: Cancer associated fibroblast gene expression patterns identify both common and unique features of tumour-stroma crosstalk across cancer types. Seminars in Cancer Biology, 2015, 35, 96-106.	9.6	85
10	Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA. Genome Medicine, 2019, 11, 1.	8.2	84
11	Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer, 2009, 9, 409.	2.6	81
12	miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death and Differentiation, 2012, 19, 1750-1760.	11.2	77
13	Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells. Cell Communication and Signaling, 2014, 12, 24.	6.5	77
14	miR-205 Hinders the Malignant Interplay Between Prostate Cancer Cells and Associated Fibroblasts. Antioxidants and Redox Signaling, 2014, 20, 1045-1059.	5.4	63
15	Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. Clinical Cancer Research, 2016, 22, 337-345.	7.0	58
16	Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts. BMC Genomics, 2018, 19, 19.	2.8	55
17	Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation. Oncotarget, 2015, 6, 31441-31460.	1.8	55
18	Comparison of Microarray Platforms for Measuring Differential MicroRNA Expression in Paired Normal/Cancer Colon Tissues. PLoS ONE, 2012, 7, e45105.	2.5	52

#	Article	IF	CITATIONS
19	Intersect-then-combine approach: improving the performance of somatic variant calling in whole exome sequencing data using multiple aligners and callers. Genome Medicine, 2017, 9, 35.	8.2	48
20	A lipemia-independent NanoDrop <sup><math>\hat{A}^{@}</math></sup> -based score to identify hemolysis in plasma and serum samples. Bioanalysis, 2014, 6, 1215-1226.	1.5	47
21	Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer. BMC Cancer, 2018, 18, 899.	2.6	45
22	Effects of Warm Ischemic Time on Gene Expression Profiling in Colorectal Cancer Tissues and Normal Mucosa. PLoS ONE, 2013, 8, e53406.	2.5	44
23	By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy. Oncotarget, 2015, 6, 2315-2330.	1.8	43
24	miR-30e* is an independent subtype-specific prognostic marker in breast cancer. British Journal of Cancer, 2015, 113, 290-298.	6.4	40
25	Subtypeâ€dependent prognostic relevance of an interferonâ€induced pathway metagene in nodeâ€negative breast cancer. Molecular Oncology, 2014, 8, 1278-1289.	4.6	39
26	Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. Nature Communications, 2021, 12, 1998.	12.8	37
27	Molecular portrait of breast cancer in <scp>C</scp> hina reveals comprehensive transcriptomic likeness to <scp>C</scp> aucasian breast cancer and low prevalence of luminal A subtype. Cancer Medicine, 2015, 4, 1016-1030.	2.8	31
28	Circulating Biomarkers for Prediction of Treatment Response. Journal of the National Cancer Institute Monographs, 2015, 2015, 60-63.	2.1	31
29	Reciprocal regulation of p63 by C/EBP delta in human keratinocytes. BMC Molecular Biology, 2007, 8, 85.	3.0	26
30	Feasibility of circulating miRNA microarray analysis from archival plasma samples. Analytical Biochemistry, 2013, 437, 123-125.	2.4	23
31	Measuring MicroRNA Expression Levels in Oncology: from Samples to Data Analysis. Critical Reviews in Oncogenesis, 2013, 18, 273-287.	0.4	21
32	AF1q: A Novel Mediator of Basal and 4-HPR-Induced Apoptosis in Ovarian Cancer Cells. PLoS ONE, 2012, 7, e39968.	2.5	19
33	Gene Expression Profiling of Circulating Tumor Cells in Breast Cancer. Clinical Chemistry, 2015, 61, 278-289.	3.2	19
34	POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. Clinical Cancer Research, 2019, 25, 6598-6605.	7.0	17
35	Proposal of supervised data analysis strategy of plasma miRNAs from hybridisation array data with an application to assess hemolysis-related deregulation. BMC Bioinformatics, 2015, 16, 388.	2.6	16
36	Use of Formalin-Fixed Paraffin-Embedded Samples for Gene Expression Studies in Breast Cancer Patients. PLoS ONE, 2015, 10, e0123194.	2.5	11

#	Article	IF	Citations
37	Involvement of AF1q/MLLT11 in the progression of ovarian cancer. Oncotarget, 2017, 8, 23246-23264.	1.8	11
38	Molecular heterogeneity in breast carcinoma cells with increased invasive capacities. Radiology and Oncology, 2020, 54, 103-118.	1.7	10
39	Accurate Data Processing Improves the Reliability of Affymetrix Gene Expression Profiles from FFPE Samples. PLoS ONE, 2014, 9, e86511.	2.5	10
40	In-depth characterization of breast cancer tumor-promoting cell transcriptome by RNA sequencing and microarrays. Oncotarget, 2016, 7, 976-994.	1.8	10
41	Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study. International Journal of Molecular Sciences, 2022, 23, 5786.	4.1	9
42	MicroRNA Detection in Plasma Samples. Journal of Molecular Diagnostics, 2013, 15, 138-139.	2.8	6
43	Prognostic and functional role of subtypeâ€specific tumor–stroma interaction in breast cancer. Molecular Oncology, 2017, 11, 1399-1412.	4.6	6
44	PATRI, a Genomics Data Integration Tool for Biomarker Discovery. BioMed Research International, 2018, 2018, 1-13.	1.9	6
45	Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts. Oncogene, 2022, 41, 112-124.	5.9	6
46	Predicting and Understanding Cancer Response to Treatment. Disease Markers, 2018, 2018, 1-2.	1.3	2
47	Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma. Genomics, 2021, 113, 3439-3448.	2.9	2
48	Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial Journal of Clinical Oncology, 2013, 31, 1014-1014.	1.6	2
49	Abstract B18: MiR-205 puts the brakes on the malignant interplay between prostate cancer cells and associated fibroblasts. , 2013, , .		1
50	Dissecting Time- from Tumor-Related Gene Expression Variability in Bilateral Breast Cancer. International Journal of Molecular Sciences, 2018, 19, 196.	4.1	0
51	An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer Journal of Clinical Oncology, 2014, 32, 530-530.	1.6	0
52	Abstract P2-03-05: The heterogeneous clinical behavior of luminal breast cancers is associated with different mutational landscapes. , $2015$ , , .		0
53	Contribution of immune system and tumor-related interferon signaling to epirubicin response in triple-negative (TN) breast cancers Journal of Clinical Oncology, 2015, 33, 1081-1081.	1.6	0
54	Abstract 5085: Cancer-associated fibroblasts transcriptional pattern reveals common changes in extracellular matrix-related genes across different cancer types. , 2016, , .		0

#	Article	IF	CITATIONS
55	Abstract 1747: A microenvironment gene signature predicts poor outcome in patients with luminal breast cancers subjected to local-regional treatment. , 2017, , .		O
56	Abstract 2991: Integrative analysis of molecular and drug response data from clinical samples and PDTXs to identify pharmacogenomic associations in breast cancer., 2017,,.		0
57	Title is missing!. , 2014, 9, e86511.		O